Session

Redefining the approach to advanced prostate cancer

Industry session by JANSSEN PHARMACEUTICA NV

  • Location:
    Room Milan, North Hall (Level 1)
  • Chairs:
     K. Fizazi, Villejuif (FR)
     K. Miller, Berlin (DE)
  • Aims and objectives of this session

    At the end of this symposium delegates should be able to:
    • Explain the importance of different mHSPC presentations and tumour load, and how this may influence management
    • Analyse the evidence for selecting a certain treatment from the current treatment options for mCRPC
    • Explain the importance of comorbidities, drug interactions, and other patient characteristics, and how these can affect treatment decisions for patients with metastatic prostate cancer
    • Describe the importance of investigating and developing biomarkers that might drive therapeutic decisions for patients with prostate cancer in the future

Welcome and introduction
 K. Miller, Berlin (DE)
Should all patients get docetaxel for metastatic hormone-sensitive prostate cancer?
 K. Fizazi, Villejuif (FR)
Should all patients get androgen-targeted therapy for first-line in metastatic castration-resistant prostate cancer?
 K. Miller, Berlin (DE)
Panel discussion - Treating the patient with metastatic disease: Clinical case discussions
 
 C.P. Evans, Sacramento (US)
 
 K. Fizazi, Villejuif (FR)
 
 K. Miller, Berlin (DE)
CRPC Variants and clinical implications
 C.P. Evans, Sacramento (US)
Close of meeting
 K. Fizazi, Villejuif (FR)